Journal List > J Korean Ophthalmol Soc > v.59(10) > 1103093

Kim and Kim: Selective Retina Therapy in Patients with Central Serous Chorioretinopathy

Abstract

Purpose

We evaluated the visual outcomes and changes in central macular thickness in patients with central serous chorior-etinopathy who underwent selective retina therapy.

Methods

Patients diagnosed with central serous chorioretinopathy were included in the study. Fundus fluorescein angiography was performed before laser treatment. We reviewed the charts of 16 patients (17 eyes) in terms of age, sex, best-corrected visu-al acuity, intraocular pressure, slit lamp examination, the time from diagnosis to laser treatment, the site of laser treatment and side-effects. Optical coherence tomography was performed before laser treatment and 1 month later; the central macular thick-nesses were compared.

Results

The average best-corrected visual acuity at diagnosis and 1 month after laser treatment were 0.20 and 0.12 (logMAR) respectively. The improvement was thus 0.08 (logMAR). The average central macular thickness decreased by 174.78 μ m from 326.53 ± 59 µm at baseline to 151.75 ± 15 μ m 1 month after selective retina therapy.

Conclusions

Selective laser therapy afforded favorable visual and structural outcomes and was not associated with a risk of scotoma or other untreatable side-effects.

References

1. Fujita K, Shinoda K, Matsumoto CS. . Microperimetric evalua-tion of chronic central serous chorioretinopathy after half-dose photodynamic therapy. Clin Ophthalmol. 2012; 6:1681–7.
2. Wang M, Munch IC, Hasler PW. . Central serous chorioretinopathy. Acta Ophthalmol. 2008; 86:126–45.
crossref
3. Oh J, Kwon OW, Kim MH. . Photodynamic therapy for chronic central serous chorioretinopathy: multicenter study of 65 cases. J Korean Ophthalmol Soc. 2009; 50:390–8.
4. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967; 63((Suppl 1)):1–139.
5. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology. 1984; 91:1554–72.
crossref
6. Yannuzzi LA, Slakter JS, Gross NE. . Indocyanine green an-giography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003; 23:288–98.
7. Hee MR, Puliafito CA, Wong C. . Optical coherence tomog-raphy of central serous chorioretinopathy. Am J Ophthalmol. 1995; 120:65–74.
crossref
8. Montero JA, Ruiz-Moreno JM. Optical coherence tomography characterisation of idiopathic central serous chorioretionpathy. Br J Ophthalmol. 2005; 89:562–4.
9. Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol. 1986; 224:321–4.
crossref
10. Spaide RF, Goldbaum M, Wong DW. . Serous detachment of the retina. Retina. 2003; 23:820–46.
crossref
11. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010; 149:361–3.
crossref
12. Quin G, Liew G, Ho IV. . Diagnosis and interventions for cen-tral serous chorioretinopathy: review and update. Clin Exp Ophthalmol. 2013; 41:187–200.
crossref
13. Wood EH, Karth PA, Sanislo SR. . Nondamaging retial laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina. 2017; 37:1021–33.
14. Roider J, Brinkmann R, Wirbelauer C. . Retinal sparing by se-lective retinal pigment epithelial photocoagulation. Arch Ophthalmol. 1999; 117:1028–34.
crossref
15. Brinkmann R, Roider J, Birngruber R. Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clin-ical results. Bull Soc Belge Ophtalmol. 2006; 302:51–69.
16. Roider J, Liew SH, Klatt C. . Selective retina therapy (SRT) for clinically significant diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010; 248:1263–72.
crossref
17. Piccolino F, Eandi CM, Ventre L. . Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003; 23:752–63.
crossref
18. Scholz P, Altay L, Fauser S. Comparison of subthreshold micro-pulse laser (577  nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond). 2016; 30:1371–7.
19. Kang S, Park YG, Kim JR. . Selective retina therapy in patients with chronic central serous chorioretinopathy: a pilot study. Medicine (Baltimore). 2016; 95:e2524.
20. Klatt C, Saeger M, Oppermann T. . Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011; 95:83–8.
crossref
21. Brinkmann R, Roider J, Birngruber R. Selective retina ther-apy(SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol. 2006; 302:51–69.
22. Elsner H, Pörksen E, Klatt C. . Selective retina therapy in pa-tients with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006; 244:1638–45.
23. Ross A, Ross AH, Mohamed Q. Review and update of central se-rous chorioretinopathy. Curr Opin Ophthalmol. 2011; 22:166–73.
crossref
24. Framme C, Walter A, Berger L. . Selective retina therapy in acute and chronic-recurrent central serous chorioretinopathy. Ophthalmologica. 2015; 234:177–88.
crossref

Figure 1.
Case 12. Selective laser therapy was applied to the leakage point which is indicated by dotted circle on fundus flu-orescin angiography at baseline.
jkos-59-915f1.tif
Figure 2.
Case 5. Large subretinal fluid was observed on base-line optical coherence tomography.
jkos-59-915f2.tif
Figure 3.
Case 5. The subretinal fluid were completely re-solved at 1 months after selective retina therapy.
jkos-59-915f3.tif
Table 1.
Characteristics of 16 patients (17 eyes) with central serous chorioretinopathy
Eye Sex Age (years) HTN/DM Side Diagnosis to laser Maximum energy (μ J) Last follow up from first laser
1 M 55 X/X L 9 months 85 5 months
2 M 39 X/X R 3 months 130 5 months
3 M 37 X/X R 5 months 110 5 months
4 F 56 X/X R 2 months 150 5 months
5 M 63 O/O R 3 months 130 5 months
6 M 57 X/X R 1 month 30 4 months
7 M 49 X/X R 3 months 90 11 months
8 M 57 X/X R 2 months 30 6 months
9 M 46 X/X R 3 months 110 Follow up loss
10 F 61 X/X R 3 week 130 6 months
11 F 61 X/X L 4 months 120 1 month
12 M 64 O/O R 2 months 130 4 months
13 M 50 O/X R 8 months 100 9 months
14 M 42 X/X L 1 month 120 2 months
15 M 53 O/X L 1 month 130 3 months
16 F 55 X/X R 1 month 140 2 months
17 M 71 O/X L 2 months 160 4 months

HTN = hypertension; DM = diabetes mellitus; M = male; F = female; L = left eye; R = right eye; O = presence; X = absence.

Table 2.
Change of best-corrected visual acuity (logMAR) in selective retina therapy-treated patients with central serous chorioretin-opathy
Eye Initial VA (logMAR) VA after therapy (logMAR) VA improvement (logMAR) p-value*
1 0.30 0.22 0.1 0.041
2 0.10 0.00 0.2
3 0.05 0.00 0.1
4 0.05 0.05 0
5 0.40 0.15 0.3
6 0.40 0.15 0.3
7 0.52 0.22 0.3
8 0.40 0.22 0.2
9 0.22 - -
10 0.05 0.05 0
11 0.05 0.05 0
12 0.00 0.00 0
13 0.15 0.00 0.3
14 0.22 0.40 -0.2
15 0.10 0.05 0.1
16 0.15 0.10 0.1
17 0.22 0.30 -0.1

VA = visual acuity.

* Wilcoxon signed rank test.

Table 3.
Change of central retinal thickness (CRT) in selective retina therapy-treated patients with central serous chorioretinopathy
Eye Baseline CRT (μ m) CRT after therapy (μ m) Decrease in CRT (μ m) p-value*
1 340 177 163 0.001
2 500 150 350
3 344 168 176
4 433 172 261
5 277 120 157
6 575 161 414
7 431 137 294
8 516 216 300
9 320 - -
10 253 133 120
11 141 121 20
12 210 94 116
13 276 144 132
14 139 178 -39
15 308 203 105
16 302 113 189
17 186 141 45

* Wilcoxon signed rank test.

TOOLS
Similar articles